Immunomediated Diseases and Innovative Therapies

Overview

The Immunomediated Diseases and Innovative Therapies is a heterogeneous area composed by both translational and clinical research groups which cover fields such as immunology, respiratory and systemic diseases, pharmacology, clinical biochemistry, rheumatology, advanced therapies or transfusional medicine. Its main strength derives precisely from this heterogeneity and the complementarity of the scientific interests and expertise of the different groups, many of which are currently joining efforts and synergizing in a variety of collaborative research projects.

Publications

268

total

1598

impact factor

5.96

average impact factor

Group Leader: Rafael Parra López

team

zoom

download

Our research activity is adressed to several related fields of interest. We are interested in transfusion of blood components, in red blood cell alterations during the conservation period and in the use of extra-corporeal photoaferesis.

We work on the molecular and serological characterization of human blood groups and we are interested in non-invasive fetal genotyping strategies to look into blood group incompatibilities. We are developing iPSC lines and making red blood cells “in vitro” with modified blood group antígens.

We explore the molecular mechanisms and the genotype-phenotype correlation of congenital coagulopaties, hemorrhagic diathesis and other associated congenital pathologies. We have developed new tools based on massive sequencing techniques applied to molecular analysis, prenatal diagnosis and genetic counselling.

Another field of interest is the study of virus and other blood borne pathogens which may pose at risk the transfusion of products supplied by the Banc de Sang i Teixits.

We investigate in clinical immunology and we have developed our own HLA and KIR typing protocols. Cell therapy is a growing field and we are interested in cord blood banking and new therapeutic uses of cord blood, in obtaining and storing virus specific T lymphocytes and in developing adoptive cell therapy in hematopoietic cell transplantation and regenrative medicine.

28

total

123

impact factor

4^.39

average impact factor

SELECTED ARTICLES

Zanetti S.R., Romecin P.A., Vinyoles M., Juan M., Fuster J.L., Cámos M., Querol S., Delgado M., Menéndez P.
Bone marrow MSC from pediatric patients with B-ALL highly immunosuppress T-cell responses but do not compromise CD19-CAR T-cell activity.
J. Immunother. Cancer 2020;8:e001419.
DOI: 10.1136/jitc-2020-001419
IF: 9.913
Martorell L, Cortina V, Parra R, Barquinero J, Vidal F.
Variable readthrough responsiveness of nonsense mutations in hemophilia A.
Haematologica. 2020 Jan 31;105(2):508-518.
DOI: 10.3324/haematol.2018.212118
IF: 7.116
Petersdorf EW, Gooley T, Volt F, Kenzey C, Madrigal A, McKallor C, Querol S, Rafii H, Rocha V, Tamouza R, Chabannon C, Ruggeri A, Gluckman E.
Use of the HLA-B leader to optimize cord-blood transplantation.
Haematologica. 2020 Oct 29.
DOI: 10.3324/haematol.2020.264424
IF: 7.116
Martín-Nalda A, Fortuny C, Rey L, Bunney TD, Alsina L, Esteve-Solé A, Bull D, Anton MC, Basagaña M, Casals F, Deyá A, García-Prat M, Gimeno R, Juan M, Martinez-Banaclocha H, Martinez-Garcia JJ, Mensa-Vilaró A, Rabionet R, Martin-Begue N, Rudilla F, Yagüe J, Estivill X, García-Patos V, Pujol RM, Soler-Palacín P, Katan M, Pelegrín P, Colobran R, Vicente A, Arostegui JI.
Severe Autoinflammatory Manifestations and Antibody Deficiency Due to Novel Hypermorphic PLCG2 Mutations.
J Clin Immunol. 2020 Oct;40(7):987-1000. Epub 2020 Jul 15.
DOI: 10.1007/s10875-020-00794-7
IF: 6.78
Rovira P, Demontis D, Sánchez-Mora C, Zayats T, Klein M, Mota NR, Weber H, Garcia-Martínez I, Pagerols M, Vilar-Ribó L, Arribas L, Richarte V, Corrales M, Fadeuilhe C, Bosch R, Martin GE, Almos P, Doyle AE, Grevet EH, Grimm O, Halmøy A, Hoogman M, Hutz M, Jacob CP, Kittel-Schneider S, Knappskog PM, Lundervold AJ, Rivero O, Rovaris DL, Salatino-Oliveira A, da Silva BS, Svirin E, Sprooten E, Strekalova T; ADHD Working Group of the Psychiatric Genomics Consortium; 23andMe Research team, Arias-Vasquez A, Sonuga-Barke EJS, Asherson P, Bau CHD, Buitelaar JK, Cormand B, Faraone SV, Haavik J, Johansson SE, Kuntsi J, Larsson H, Lesch KP, Reif A, Rohde LA, Casas M, Børglum AD, Franke B, Ramos-Quiroga JA, Soler Artigas M, Ribasés M.
Shared genetic background between children and adults with attention deficit/hyperactivity disorder.
Neuropsychopharmacology. 2020 Sep;45(10):1617-1626. Epub 2020 Apr 12.
DOI: 10.1038/s41386-020-0664-5
IF: 6.751

View all publications

Immunomediated Diseases and Innovative Therapies

Overview

Publications

Group Leader: Rafael Parra López

Research Areas